Zentalis To Present Azenosertib Phase 2 DENALI Trial Data At SGO 2025, Highlighting Biomarker Insights

Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company developing a potentially best-in-class WEE1 inhibitor for ovarian cancer and other tumours, has announced multiple presentations at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer. The annual conference will take place across three days from March 14-17 in Seattle, Washington and will present updated information about the clinical trial results from Phase 2 DENALI research involving azenosertib for platinum-resistant ovarian cancer (PROC). 

The oral presentation, delivered by Dr Fiona Simpkins, will highlight findings from Part 1b of the DENALI study, showcasing Cyclin E1 as a predictive biomarker for azenosertib’s benefit in PROC patients. This session, titled "Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes from Part 1b of the DENALI Study (GOG-3066)," is scheduled for March 15 at 8:25 AM PST during the Scientific Plenary II: Hitting the Target - Maximizing IMPACT session.

Additionally, Dr Joanna Guo will present a poster exploring azenosertib’s synergistic antitumor effects when combined with microtubule inhibitor-based antibody-drug conjugates (ADCs) in preclinical models. This session, titled "The WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Effects With Microtubule Inhibitor–Based Antibody Drug Conjugates (ADCs) in Preclinical Models," will be held on March 16 during two in-person poster sessions.